Karachi: Citi Pharma Limited has disclosed a year of significant transformation and progress, according to the Chairman's Review on the board's performance for the financial year ended June 30, 2024. The pharmaceutical company has expanded its operations, secured key international partnerships, and reported robust growth in profitability, all under the strategic direction of its Board of Directors.

According to information available from the Pakistan Stock Exchange (PSX), the company's board has been instrumental in implementing decisions that enhanced operational efficiencies, expanded product offerings, and strengthened international partnerships. These initiatives have been pivotal in driving the company's performance throughout the fiscal year.

The review highlighted the board's effective navigation of macroeconomic uncertainties, emphasizing risk management and sustainability. This proactive governance helped maintain the company's compliance with stringent regulatory standards, especially in health and safety protocols, reinforcing Citi Pharma's reputation as a responsible corporate entity.

Furthermore, the board's focus on fostering a culture of innovation and adaptability has allowed the company to successfully manage market fluctuations and capitalize on emerging opportunities. The annual assessment confirmed that the board and its committees have performed satisfactorily and effectively, maintaining good governance practices that are crucial for sustaining shareholder value.

Expressing his gratitude, the Chairman thanked the board members for their guidance and the company's stakeholders for their continuous support. The dedication of Citi Pharma’s employees was also acknowledged as a key factor in the company’s ongoing success.

Looking forward, the board remains optimistic about the future prospects of Citi Pharma Limited. With plans for further expansions, new collaborations, and continuous improvements in operational efficiencies, the company is well-positioned to enhance its financial performance and stakeholder value in the coming years.